HIV-1 entry inhibitors: Recent development and clinical use

Current Opinion in Virology

Volumn 3, Issue 1, 2013, Pages 51-57

  Henrich, Timothy J ^a   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; APLAVIROC; CD4 IMMUNOGLOBULIN G2; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; IBALIZUMAB; MARAVIROC; PLERIXAFOR; SIFUVIRTIDE; VICRIVIROC;

ANTIVIRAL ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; DISEASE TRANSMISSION, INFECTIOUS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; ORGANOPHOSPHATES; PIPERAZINES; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 84874660180     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.12.002     Document Type: Review

References (60)

1. P.D. Kwong, R. Wyatt, Q.J. Sattentau, J. Sodroski, and W.A. Hendrickson Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus J Virol 74 2000 1961 1972 (Pubitemid 30434055)
2. C.D. Weiss, J.A. Levy, and J.M. White Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles J Virol 64 1990 5674 5677 (Pubitemid 20364569)
3. D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273 (Pubitemid 27199898)
4. E.S. Daar, X.L. Li, T. Moudgil, and D.D. Ho High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates Proc Natl Acad Sci U S A 87 1990 6574 6578
5. R.T. Schooley, T.C. Merigan, P. Gaut, M.S. Hirsch, M. Holodniy, T. Flynn, S. Liu, R.E. Byington, S. Henochowicz, and E. Gubish Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial Ann Intern Med 112 1990 247 253 (Pubitemid 20055349)
6. S. Turner, R. Tizard, J. DeMarinis, R.B. Pepinsky, J. Zullo, R. Schooley, and R. Fisher Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120 Proc Natl Acad Sci U S A 89 1992 1335 1339
7. R.T. Davey Jr., C.M. Boenning, B.R. Herpin, D.H. Batts, J.A. Metcalf, L. Wathen, S.R. Cox, M.A. Polis, J.A. Kovacs, and J. Falloon Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus J Infect Dis 170 1994 1180 1188 (Pubitemid 24328621)
8. G.P. Allaway, K.L. Davis-Bruno, G.A. Beaudry, E.B. Garcia, E.L. Wong, A.M. Ryder, K.W. Hasel, M.C. Gauduin, R.A. Koup, and J.S. McDougal Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates AIDS Res Hum Retroviruses 11 1995 533 539
9. J.M. Jacobson, R.J. Israel, I. Lowy, N.A. Ostrow, L.S. Vassilatos, M. Barish, D.N. Tran, B.M. Sullivan, T.J. Ketas, and T.J. O'Neill Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542 Antimicrob Agents Chemother 48 2004 423 429 (Pubitemid 38141697)
10. Q. Guo, H.T. Ho, I. Dicker, L. Fan, N. Zhou, J. Friborg, T. Wang, B.V. McAuliffe, H.G. Wang, and R.E. Rose Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions J Virol 77 2003 10528 10536 (Pubitemid 37129696)
11. P.F. Lin, W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y.F. Gong, H.G. Wang, R. Rose, and G. Yamanaka A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding Proc Natl Acad Sci U S A 100 2003 11013 11018 (Pubitemid 37140144)
12. G.J. Hanna, J. Lalezari, J.A. Hellinger, D.A. Wohl, R. Nettles, A. Persson, M. Krystal, P. Lin, R. Colonno, and D.M. Grasela Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects Antimicrob Agents Chemother 55 2011 722 728
13. B. Nowicka-Sans, Y.F. Gong, B. McAuliffe, I. Dicker, H.T. Ho, N. Zhou, B. Eggers, P.F. Lin, N. Ray, and M. Wind-Rotolo In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068 Antimicrob Agents Chemother 56 2012 3498 3507
14. R.E. Nettles, D. Schurmann, L. Zhu, M. Stonier, S.P. Huang, I. Chang, C. Chien, M. Krystal, M. Wind-Rotolo, and N. Ray Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects J Infect Dis 206 2012 1002 1011
15. L.C. Burkly, D. Olson, R. Shapiro, G. Winkler, J.J. Rosa, D.W. Thomas, C. Williams, and P. Chisholm Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion J Immunol 149 1992 1779 1787
16. L. Boon, B. Holland, W. Gordon, P. Liu, F. Shiau, W. Shanahan, K.A. Reimann, and M. Fung Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates Toxicology 172 2002 191 203 (Pubitemid 34219385)
17. L. Burkly, N. Mulrey, R. Blumenthal, and D.S. Dimitrov Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies J Virol 69 1995 4267 4273
18. K.A. Reimann, W. Lin, S. Bixler, B. Browning, B.N. Ehrenfels, J. Lucci, K. Miatkowski, D. Olson, T.H. Parish, and M.D. Rosa A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties AIDS Res Hum Retroviruses 13 1997 933 943 (Pubitemid 27334699)
19. X.Q. Zhang, M. Sorensen, M. Fung, and R.T. Schooley Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20) Antimicrob Agents Chemother 50 2006 2231 2233 (Pubitemid 43807552)
20. D.R. Kuritzkes, J. Jacobson, W.G. Powderly, E. Godofsky, E. DeJesus, F. Haas, K.A. Reimann, J.L. Larson, P.O. Yarbough, and V. Curt Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1 J Infect Dis 189 2004 286 291 (Pubitemid 38147253)
21. J.M. Jacobson, D.R. Kuritzkes, E. Godofsky, E. DeJesus, J.A. Larson, S.P. Weinheimer, and S.T. Lewis Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults Antimicrob Agents Chemother 53 2009 450 457
22. D. Norris, J. Morales, J. Gathe, E. Godofsky, F. Garcia, R. Hardwicke, and S. Lewis Phase 2 efficacy and safety of the novel entry inhibitor, TNX-355, in combinatio nwith optimized background regimen (OBR) Programme & Abstracts of the XVI International AIDS Conference Toronto, ON, Canada, August 13-18 [Abstract THLB0218] 2006
23. H. Khanlou, J. Gathe, S. Schrader, W. Towner, S. Weinheimer, and S. Lewis Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study Program and Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA, September 17-20 2011
24. W.J. Fessel, B. Anderson, S.E. Follansbee, M.A. Winters, S.T. Lewis, S.P. Weinheimer, C.J. Petropoulos, and R.W. Shafer The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment Antiviral Res 92 2011 484 487
25. J. Toma, S.P. Weinheimer, E. Stawiski, J.M. Whitcomb, S.T. Lewis, C.J. Petropoulos, and W. Huang Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab J Virol 85 2011 3872 3880
26. C.S. Pace, M.W. Fordyce, D. Franco, C.Y. Kao, M.S. Seaman, and D.D. Ho Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope J Acquir Immune Defic Syndr 62 2013 1 9
27. Z.L. Brumme, J. Goodrich, H.B. Mayer, C.J. Brumme, B.M. Henrick, B. Wynhoven, J.J. Asselin, P.K. Cheung, R.S. Hogg, and J.S. Montaner Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals J Infect Dis 192 2005 466 474 (Pubitemid 41023125)
28. G.J. Moyle, A. Wildfire, S. Mandalia, H. Mayer, J. Goodrich, J. Whitcomb, and B.G. Gazzard Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection J Infect Dis 191 2005 866 872 (Pubitemid 40349800)
29. L. Waters, S. Mandalia, P. Randell, A. Wildfire, B. Gazzard, and G. Moyle The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen Clin Infect Dis 46 2008 1617 1623 (Pubitemid 351706746)
30. J. Lalezari, M. Thompson, P. Kumar, P. Piliero, R. Davey, K. Patterson, A. Shachoy-Clark, K. Adkison, J. Demarest, and Y. Lou Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults AIDS 19 2005 1443 1448 (Pubitemid 41400688)
31. W.G. Nichols, H.M. Steel, T. Bonny, K. Adkison, L. Curtis, J. Millard, K. Kabeya, and N. Clumeck Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) Antimicrob Agents Chemother 52 2008 858 865 (Pubitemid 351358363)
32. R.M. Gulick, Z. Su, C. Flexner, M.D. Hughes, P.R. Skolnik, T.J. Wilkin, R. Gross, A. Krambrink, E. Coakley, and W.L. Greaves Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 J Infect Dis 196 2007 304 312 (Pubitemid 47047471)
33. D. Schurmann, G. Fatkenheuer, J. Reynes, C. Michelet, F. Raffi, J. van Lier, M. Caceres, A. Keung, A. Sansone-Parsons, and L.M. Dunkle Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults AIDS 21 2007 1293 1299 (Pubitemid 46883483)
34. R.J. Landovitz, J.B. Angel, C. Hoffmann, H. Horst, M. Opravil, J. Long, W. Greaves, and G. Fatkenheuer Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection J Infect Dis 198 2008 1113 1122
35. M.M. Caseiro, M. Nelson, R.S. Diaz, J. Gathe, J.L. de Andrade Neto, J. Slim, A. Solano, E.M. Netto, C. Mak, and J. Shen Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials J Infect 65 2012 326 335
36. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, and C. Napier Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob Agents Chemother 49 2005 4721 4732 (Pubitemid 41552605)
37. G. Fatkenheuer, M. Nelson, A. Lazzarin, I. Konourina, A.I. Hoepelman, H. Lampiris, B. Hirschel, P. Tebas, F. Raffi, and B. Trottier Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection N Engl J Med 359 2008 1442 1455
38. R.M. Gulick, J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, J. Nadler, B. Clotet, A. Karlsson, and M. Wohlfeiler Maraviroc for previously treated patients with R5 HIV-1 infection N Engl J Med 359 2008 1429 1441
39. W.D. Hardy, R.M. Gulick, H. Mayer, G. Fatkenheuer, M. Nelson, J. Heera, N. Rajicic, and J. Goodrich Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2 J Acquir Immune Defic Syndr 55 2010 558 564
40. M. Saag, J. Goodrich, G. Fatkenheuer, B. Clotet, N. Clumeck, J. Sullivan, M. Westby, E. van der Ryst, and H. Mayer A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1 J Infect Dis 199 2009 1638 1647
41. D.A. Cooper, J. Heera, J. Goodrich, M. Tawadrous, M. Saag, E. Dejesus, N. Clumeck, S. Walmsley, N. Ting, and E. Coakley Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection J Infect Dis 201 2010 803 813
42. J. Sierra-Madero, G. Di Perri, R. Wood, M. Saag, I. Frank, C. Craig, R. Burnside, J. McCracken, D. Pontani, and J. Goodrich Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study HIV Clin Trials 11 2010 125 132
43. T.J. Wilkin, C.M. Lalama, J. McKinnon, R.T. Gandhi, N. Lin, A. Landay, H. Ribaudo, L. Fox, J.S. Currier, and J.W. Mellors A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4(+) T-cell recovery despite sustained virologic suppression: ACTG A5256 J Infect Dis 206 2012 534 542
44. C. Gutierrez, L. Diaz, A. Vallejo, B. Hernandez-Novoa, M. Abad, N. Madrid, V. Dahl, R. Rubio, A.M. Moreno, and F. Dronda Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected PLoS One 6 2011 e27864
45. R.S. Veazey, T.J. Ketas, J. Dufour, T. Moroney-Rasmussen, L.C. Green, P.J. Klasse, and J.P. Moore Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor J Infect Dis 202 2010 739 744
46. J. Lalezari, J. Gathe, C. Brinson, M. Thompson, C. Cohen, E. Dejesus, J. Galindez, J.A. Ernst, D.E. Martin, and S.M. Palleja Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects J Acquir Immune Defic Syndr 57 2011 118 125
47. J.F. Marier, M. Trinh, L.H. Pheng, S.M. Palleja, and D.E. Martin Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients Antimicrob Agents Chemother 55 2011 2768 2774
48. T. Melby, M. Despirito, R. Demasi, G. Heilek-Snyder, M.L. Greenberg, and N. Graham HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response J Infect Dis 194 2006 238 246 (Pubitemid 44087196)
49. C.W. Hendrix, C. Flexner, R.T. MacFarland, C. Giandomenico, E.J. Fuchs, E. Redpath, G. Bridger, and G.W. Henson Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers Antimicrob Agents Chemother 44 2000 1667 1673 (Pubitemid 30340812)
50. N. Flomenberg, J. DiPersio, and G. Calandra Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells Acta Haematol 114 2005 198 205 (Pubitemid 41567002)
51. C.T. Wild, D.C. Shugars, T.K. Greenwell, C.B. McDanal, and T.J. Matthews Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc Natl Acad Sci U S A 91 1994 9770 9774 (Pubitemid 24311889)
52. J.P. Lalezari, K. Henry, M. O'Hearn, J.S. Montaner, P.J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D.R. Kuritzkes, and J.J. Eron Jr. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America N Engl J Med 348 2003 2175 2185 (Pubitemid 36618128)
53. A. Lazzarin, B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H.J. Stellbrink, J.F. Delfraissy, and J. Lange Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia N Engl J Med 348 2003 2186 2195 (Pubitemid 36618129)
54. B. Clotet, N. Bellos, J.M. Molina, D. Cooper, J.C. Goffard, A. Lazzarin, A. Wohrmann, C. Katlama, T. Wilkin, and R. Haubrich Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Lancet 369 2007 1169 1178 (Pubitemid 46541620)
55. C.B. Hicks, P. Cahn, D.A. Cooper, S.L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M.A. Johnson, D. Neubacher, and D. Mayers Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Lancet 368 2006 466 475 (Pubitemid 44142769)
56. J. Lu, S.G. Deeks, R. Hoh, G. Beatty, B.A. Kuritzkes, J.N. Martin, and D.R. Kuritzkes Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis J Acquir Immune Defic Syndr 43 2006 60 64 (Pubitemid 44306489)
57. X. Yao, H. Chong, C. Zhang, S. Waltersperger, M. Wang, S. Cui, and Y. He Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide J Biol Chem 287 2012 6788 6796
58. Y. He, Y. Xiao, H. Song, Q. Liang, D. Ju, X. Chen, H. Lu, W. Jing, S. Jiang, and L. Zhang Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor J Biol Chem 283 2008 11126 11134
59. Z. Liu, M. Shan, L. Li, L. Lu, S. Meng, C. Chen, Y. He, S. Jiang, and L. Zhang In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor J Biol Chem 286 2011 3277 3287
60. B. Berkhout, D. Eggink, and R.W. Sanders Is there a future for antiviral fusion inhibitors? Curr Opin Virol 2 2012 50 59